Keith Elliston Email & Phone Number

Bedford, MA, US

Bedford, Massachusetts, US

I co-founded and lead Axiomedix, which was formed to provide a commercial support and hosting platform for the open source tools of the i2b2 tranSMART foundation, and to build on these platforms to establish a large-scale federation capability to support precision medicine. Axiomedix provides a hosted, open-source platform for precision medicine, and.

Seneca Creek Ventures is a small venture studio that builds new companies in the biotech, pharma, health and AI spaces.

Bedford, Massachusetts, US

Systems Biology, Data Science, Drug Discovery and Startup launchpad, serving partners in the biotech, pharmaceutical, venture capital and non-profit foundation arenas. Specializing in the application of information technologies, data science and genomics to drug discovery and patient care. Clients have included: Hewlett Packard, Atlas Ventures, Oak.

Bangalore, IN

I am working with the Open Source Pharma Foundation to develop a new paradigm and methods for open and collaborative drug discovery. Our efforts are focused on discovering new and affordable treatments for third world diseases, and developing a new, open and collaborative approach to drug discovery.

Bedford, MA, US

Ingentium is a scientific and medical media company using an artificial intelligence based platform to digest huge volumes of healthcare media and data into tractable medically actionable deliverables. These include deep dynamic disease-focused knowlegebases (D3K), disease and mechanism specific scientific and medical journals and newsfeeds, and.

Vancouver, British Columbia, CA

Repositioned the company into a health data as as service, pivoted the platform to a cloud native solution, and successfully marketed and sold the business.

Wakefield, MA, US

I was the Executive Director of the i2b2 tranSMART Foundation, a 501c3 non-profit open-source, open-data foundation focused on enabling the promise of precision medicine. I led the merger between the tranSMART Foundation and the i2b2 Foundation. The i2b2 tranSMART Foundation was formed by merging the i2b2 Foundation, an open-source software foundation.

Boston, MA, US

Responsible for overall direction and leadership for the open-source, open-data tranSMART Foundation. Established the membership program, led the development and delivery of v1.2 of the platform, and established and lead the management team.

Boston, MA, US

Co-founded the successor tranSMART Foundation with Brian Athey, Kevin Smith, Yike Guo, and Michael Braxenthaler. Led the project management for v1.1, development and implementation of the membership program, business development, and management of the content committee, as well as serving as a key business advisor.

Boston, MA, US

Served as a board member of the predecessor tranSMART Foundation, which was established as a 501c6 (trade organization) to coordinate the initial contribution of tranSMART to the open-source community. The current tranSMART Foundation was established as a successor 501c3 non-profit charity, to expand the mission of the Foundation and to establish a vibrant.

New York, NY, US

I led the preclinical, early discovery efforts of the CHDI foundation's drug discovery R&D, implementing systems biology as the platform to define and model Huntington's disease in order to effectively and efficiently find treatments for the disease. My responsibilities included developing and managing 5 platform teams (Computational and Wet Biology), 7.

Hyderabad, IN

Contributed to the development of a virtual imaging corelab using a cloud computing infrastructure. Spun off a dedicated core lab through a strategic partnership with a lead Radiology practice.

Cambridge, MA, US

Founded successful Systems Biology company, developed an Artificial Intelligence platform to model biological systems, and drove the business to cash flow breakeven in 2006 and cash flow positive for FY2008 and 2009 on a $6.5 Venture Capital investment.

Co-founder of a discovery informatics application service provider. Developed proprietary platform offering secure applications to pharmaceutical, biotechnology and academic centers. Led the successful sale of the company to an investor group.

Developed the strategy for the pharmaceutical business efforts of the company, and advised the management team and board on financing and business development strategies.

Gaithersburg, MD, US

Developed company from early stage through IPO, closed and managed 6 corporate discovery partnerships worth ~$350M in potential revenues. Founded and was President of the bioinformatics systems division.

Leverkusen, North Rhine-Westphalia, DE

Founding head of Genomics and World Wide head of Bioinformatics at Bayer AG. Developed the strategy for bioinformatics and genomics efforts in the pharmaceutical division, and delivered 5 novel targets for high throughput screening.

Rahway, New Jersey, US

I co-founded, directed and managed the Merck Gene Index project, a privately funded public genome project that published the first sequence characterization of over 85% of the transcribed human genome. These data became the framework for the first assembly of the human genome by the Human Genome Project.

Rahway, New Jersey, US

Founded and directed the department of bioinformatics. Founded and directed the Merck Gene Index Project. Proposed and managed the implementation of Merck's connectivity to the Internet (1993).

Doctor Of Philosophy (Ph.D.), Molecular Genetics

Education record

Master’S Degree (Ms), Genetics

Bachelor’S Degree, Biology / Environmental Studies